Biological immunotherapy is widely accepted by patients because of its low side effects and is called “green therapy”. Individualized immunotherapy is the new hot spot in the field of immunotherapy in recent years. Overseas studies have confirmed that individualized selection of tumor antigen peptide according to HLA genotyping and tumor tissue antigen expression can effectively stimulate the immune response of patients and prolong the survival of patients. The key of anti-tumor immune response is that antigen-presenting cells (APC) present tumor-associated antigens to T cells and activate the body’s cellular immune system to remove tumor cells. It has been shown that the presentation of tumor antigens must first be degraded by APCs into short peptides, which then bind to major histocompatibility complex (MHC) molecules to form peptide-MHC-TCR complexes before being presented on the cell surface for recognition by T cells and to stimulate specific T killer cell (CTL) responses. Dendritic cells (DCs) are the most functional antigen-presenting cells known. The ability of peptide vaccines, peptide-stimulated dendritic cell tumor vaccines and antigen-specific T cells cultured in vitro and then returned for infusion to produce antitumor immunity depends on good binding to human leukocyte antigen (HLA) antigen molecules and antigenic determinant clusters. Precise antigen mapping is a key factor for the successful efficacy of tumor vaccines. Based on the international clinical research reports, our center has selected peptides that have been proven to be effective in gastric cancer treatment and constructed a gastric cancer individualized peptide library containing more than dozens of peptides; we also use advanced SSP technology and flow cytometry technology to analyze the HLA phenotype of patients and immunohistochemistry technology to analyze the antigen expression of patients’ tumor tissues, so as to finely screen individualized antigen peptides for each patient and achieve The precise antigen typing of “tailor-made” type. The individualized peptide is loaded with DC vaccine in the laminar flow cell culture room of international standard, and the immunocidal cells are activated in vitro and then transfused back to the patient, providing a “green” treatment pathway for patients with refractory gastric cancer. This technology can also be combined with local radiotherapy and chemotherapy to further improve the efficiency. Patients have no toxic side effects except mild fever and slight itching of the skin at the site of cell transfusion, and it is well tolerated.